Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 189

1.

MTAP Loss Promotes Stemness in Glioblastoma and Confers Unique Susceptibility to Purine Starvation.

Hansen LJ, Sun R, Yang R, Singh SX, Chen LH, Pirozzi CJ, Moure CJ, Hemphill C, Carpenter AB, Healy P, Ruger RC, Chen CJ, Greer PK, Zhao F, Spasojevic I, Grenier C, Huang Z, Murphy SK, McLendon RE, Friedman HS, Friedman AH, Herndon JE 2nd, Sampson JH, Keir ST, Bigner DD, Yan H, He Y.

Cancer Res. 2019 Jul 1;79(13):3383-3394. doi: 10.1158/0008-5472.CAN-18-1010. Epub 2019 Apr 30.

PMID:
31040154
2.

Synergistic antitumor effects of 9.2.27-PE38KDEL and ABT-737 in primary and metastatic brain tumors.

Yu X, Dobrikov M, Keir ST, Gromeier M, Pastan IH, Reisfeld R, Bigner DD, Chandramohan V.

PLoS One. 2019 Jan 9;14(1):e0210608. doi: 10.1371/journal.pone.0210608. eCollection 2019.

3.

Correction: Reversing the Warburg effect as a treatment for glioblastoma.

Poteet E, Choudhury GR, Winters A, Li W, Ryou MG, Liu R, Tang L, Ghorpade A, Wen Y, Yuan F, Keir ST, Yan H, Bigner DD, Simpkins JW, Yang SH.

J Biol Chem. 2018 Sep 28;293(39):14973. doi: 10.1074/jbc.AAC118.005625. No abstract available.

4.

Bevacizumab, irinotecan, temozolomide, tyrosine kinase inhibition, and MEK inhibition are effective against pleomorphic xanthoastrocytoma regardless of V600E status.

Thompson EM, Landi D, Ashley D, Keir ST, Bigner D.

J Neurooncol. 2018 Nov;140(2):261-268. doi: 10.1007/s11060-018-2975-5. Epub 2018 Aug 17.

PMID:
30120661
5.

A Rationally Designed Fully Human EGFRvIII:CD3-Targeted Bispecific Antibody Redirects Human T Cells to Treat Patient-derived Intracerebral Malignant Glioma.

Gedeon PC, Schaller TH, Chitneni SK, Choi BD, Kuan CT, Suryadevara CM, Snyder DJ, Schmittling RJ, Szafranski SE, Cui X, Healy PN, Herndon JE 2nd, McLendon RE, Keir ST, Archer GE, Reap EA, Sanchez-Perez L, Bigner DD, Sampson JH.

Clin Cancer Res. 2018 Aug 1;24(15):3611-3631. doi: 10.1158/1078-0432.CCR-17-0126. Epub 2018 Apr 27.

6.

Sym004-induced EGFR elimination is associated with profound anti-tumor activity in EGFRvIII patient-derived glioblastoma models.

Keir ST, Chandramohan V, Hemphill CD, Grandal MM, Melander MC, Pedersen MW, Horak ID, Kragh M, Desjardins A, Friedman HS, Bigner DD.

J Neurooncol. 2018 Jul;138(3):489-498. doi: 10.1007/s11060-018-2832-6. Epub 2018 Mar 21.

7.

A novel method for studying airway hyperresponsiveness in allergic guinea pigs in vivo using the PreciseInhale system for delivery of dry powder aerosols.

Lexmond AJ, Keir S, Terakosolphan W, Page CP, Forbes B.

Drug Deliv Transl Res. 2018 Jun;8(3):760-769. doi: 10.1007/s13346-018-0490-z.

8.

Therapeutic targeting of ependymoma as informed by oncogenic enhancer profiling.

Mack SC, Pajtler KW, Chavez L, Okonechnikov K, Bertrand KC, Wang X, Erkek S, Federation A, Song A, Lee C, Wang X, McDonald L, Morrow JJ, Saiakhova A, Sin-Chan P, Wu Q, Michaelraj KA, Miller TE, Hubert CG, Ryzhova M, Garzia L, Donovan L, Dombrowski S, Factor DC, Luu B, Valentim CLL, Gimple RC, Morton A, Kim L, Prager BC, Lee JJY, Wu X, Zuccaro J, Thompson Y, Holgado BL, Reimand J, Ke SQ, Tropper A, Lai S, Vijayarajah S, Doan S, Mahadev V, Miñan AF, Gröbner SN, Lienhard M, Zapatka M, Huang Z, Aldape KD, Carcaboso AM, Houghton PJ, Keir ST, Milde T, Witt H, Li Y, Li CJ, Bian XW, Jones DTW, Scott I, Singh SK, Huang A, Dirks PB, Bouffet E, Bradner JE, Ramaswamy V, Jabado N, Rutka JT, Northcott PA, Lupien M, Lichter P, Korshunov A, Scacheri PC, Pfister SM, Kool M, Taylor MD, Rich JN.

Nature. 2018 Jan 4;553(7686):101-105. doi: 10.1038/nature25169. Epub 2017 Dec 20.

9.

Validation of an Immunohistochemistry Assay for Detection of CD155, the Poliovirus Receptor, in Malignant Gliomas.

Chandramohan V, Bryant JD, Piao H, Keir ST, Lipp ES, Lefaivre M, Perkinson K, Bigner DD, Gromeier M, McLendon RE.

Arch Pathol Lab Med. 2017 Dec;141(12):1697-1704. doi: 10.5858/arpa.2016-0580-OA. Epub 2017 Aug 22.

10.

A cross sectional analysis from a single institution's experience of psychosocial distress and health-related quality of life in the primary brain tumor population.

Randazzo DM, McSherry F, Herndon JE 2nd, Affronti ML, Lipp ES, Flahiff C, Miller E, Woodring S, Freeman M, Healy P, Minchew J, Boulton S, Desjardins A, Vlahovic G, Friedman HS, Keir S, Peters KB.

J Neurooncol. 2017 Sep;134(2):363-369. doi: 10.1007/s11060-017-2535-4. Epub 2017 Jul 1.

PMID:
28669010
11.

The role of angiogenesis in Group 3 medulloblastoma pathogenesis and survival.

Thompson EM, Keir ST, Venkatraman T, Lascola C, Yeom KW, Nixon AB, Liu Y, Picard D, Remke M, Bigner DD, Ramaswamy V, Taylor MD.

Neuro Oncol. 2017 Sep 1;19(9):1217-1227. doi: 10.1093/neuonc/nox033.

12.

Initial testing of VS-4718, a novel inhibitor of focal adhesion kinase (FAK), against pediatric tumor models by the Pediatric Preclinical Testing Program.

Kurmasheva RT, Gorlick R, Kolb EA, Keir ST, Maris JM, Lock RB, Carol H, Kang M, Reynolds CP, Wu J, Houghton PJ, Smith MA.

Pediatr Blood Cancer. 2017 Apr;64(4). doi: 10.1002/pbc.26304. Epub 2016 Oct 27.

13.

Initial testing (stage 1) of the curaxin CBL0137 by the pediatric preclinical testing program.

Lock R, Carol H, Maris JM, Kolb EA, Gorlick R, Reynolds CP, Kang MH, Keir ST, Wu J, Purmal A, Gudkov A, Kurmashev D, Kurmasheva RT, Houghton PJ, Smith MA.

Pediatr Blood Cancer. 2017 Apr;64(4). doi: 10.1002/pbc.26263. Epub 2016 Sep 21.

14.

Using Salt Counterions to Modify β2-Agonist Behavior in Vivo.

Patel A, Keir SD, Brown MB, Hider R, Jones SA, Page CP.

Mol Pharm. 2016 Oct 3;13(10):3439-3448. Epub 2016 Aug 29.

15.

Evaluation of Alternative In Vivo Drug Screening Methodology: A Single Mouse Analysis.

Murphy B, Yin H, Maris JM, Kolb EA, Gorlick R, Reynolds CP, Kang MH, Keir ST, Kurmasheva RT, Dvorchik I, Wu J, Billups CA, Boateng N, Smith MA, Lock RB, Houghton PJ.

Cancer Res. 2016 Oct 1;76(19):5798-5809. Epub 2016 Aug 5.

16.

Initial Testing (Stage 1) of MK-8242-A Novel MDM2 Inhibitor-by the Pediatric Preclinical Testing Program.

Kang MH, Reynolds CP, Kolb EA, Gorlick R, Carol H, Lock R, Keir ST, Maris JM, Wu J, Lyalin D, Kurmasheva RT, Houghton PJ, Smith MA.

Pediatr Blood Cancer. 2016 Oct;63(10):1744-52. doi: 10.1002/pbc.26064. Epub 2016 May 30.

17.

A Therapeutic Antibody for Cancer, Derived from Single Human B Cells.

Bushey RT, Moody MA, Nicely NL, Haynes BF, Alam SM, Keir ST, Bentley RC, Roy Choudhury K, Gottlin EB, Campa MJ, Liao HX, Patz EF Jr.

Cell Rep. 2016 May 17;15(7):1505-1513. doi: 10.1016/j.celrep.2016.04.038. Epub 2016 May 5.

18.

Facilitators and Barriers of Implementing a Measurement Feedback System in Public Youth Mental Health.

Kotte A, Hill KA, Mah AC, Korathu-Larson PA, Au JR, Izmirian S, Keir SS, Nakamura BJ, Higa-McMillan CK.

Adm Policy Ment Health. 2016 Nov;43(6):861-878.

PMID:
27000148
19.

Initial Testing of NSC 750854, a Novel Purine Analog, Against Pediatric Tumor Models by the Pediatric Preclinical Testing Program.

Gorlick R, Kolb EA, Keir ST, Maris JM, Lock RB, Carol H, Reynolds CP, Kang MH, Billups CA, Collins J, Kurmashev D, Kurmasheva RT, Houghton PJ, Smith MA.

Pediatr Blood Cancer. 2016 Mar;63(3):443-50. doi: 10.1002/pbc.25826. Epub 2015 Nov 24.

20.

MiR-215 Is Induced Post-transcriptionally via HIF-Drosha Complex and Mediates Glioma-Initiating Cell Adaptation to Hypoxia by Targeting KDM1B.

Hu J, Sun T, Wang H, Chen Z, Wang S, Yuan L, Liu T, Li HR, Wang P, Feng Y, Wang Q, McLendon RE, Friedman AH, Keir ST, Bigner DD, Rathmell J, Fu XD, Li QJ, Wang H, Wang XF.

Cancer Cell. 2016 Jan 11;29(1):49-60. doi: 10.1016/j.ccell.2015.12.005.

21.

Reliable Change and Outcome Trajectories Across Levels of Care in a Mental Health System for Youth.

Jackson DS, Keir SS, Sender M, Mueller CW.

Adm Policy Ment Health. 2017 Jan;44(1):141-154. doi: 10.1007/s10488-015-0690-5.

PMID:
26459353
22.
23.

Pharmacodynamic and genomic markers associated with response to the XPO1/CRM1 inhibitor selinexor (KPT-330): A report from the pediatric preclinical testing program.

Attiyeh EF, Maris JM, Lock R, Reynolds CP, Kang MH, Carol H, Gorlick R, Kolb EA, Keir ST, Wu J, Landesman Y, Shacham S, Lyalin D, Kurmasheva RT, Houghton PJ, Smith MA.

Pediatr Blood Cancer. 2016 Feb;63(2):276-86. doi: 10.1002/pbc.25727. Epub 2015 Sep 23.

24.

Bradykinin and capsaicin induced airways obstruction in the guinea pig are platelet dependent.

Keir SD, Spina D, Page CP.

Pulm Pharmacol Ther. 2015 Aug;33:25-31. doi: 10.1016/j.pupt.2015.05.004. Epub 2015 May 23.

PMID:
26006082
25.

Dynamic treatment effect (DTE) curves reveal the mode of action for standard and experimental cancer therapies.

Choudhury KR, Keir ST, Ashcraft KA, Boss MK, Dewhirst MW.

Oncotarget. 2015 Jun 10;6(16):14656-68.

26.

Proteomic profiling of patient-derived glioblastoma xenografts identifies a subset with activated EGFR: implications for drug development.

Brown KE, Chagoya G, Kwatra SG, Yen T, Keir ST, Cooter M, Hoadley KA, Rasheed A, Lipp ES, Mclendon R, Ali-Osman F, Bigner DD, Sampson JH, Kwatra MM.

J Neurochem. 2015 Jun;133(5):730-8. doi: 10.1111/jnc.13032. Epub 2015 Feb 12.

27.

Synergistic activity of PARP inhibition by talazoparib (BMN 673) with temozolomide in pediatric cancer models in the pediatric preclinical testing program.

Smith MA, Reynolds CP, Kang MH, Kolb EA, Gorlick R, Carol H, Lock RB, Keir ST, Maris JM, Billups CA, Lyalin D, Kurmasheva RT, Houghton PJ.

Clin Cancer Res. 2015 Feb 15;21(4):819-32. doi: 10.1158/1078-0432.CCR-14-2572. Epub 2014 Dec 10. Erratum in: Clin Cancer Res. 2017 Feb 15;23 (4):1118-1119.

28.

RhoA signaling through platelet P2Y₁ receptor controls leukocyte recruitment in allergic mice.

Amison RT, Momi S, Morris A, Manni G, Keir S, Gresele P, Page CP, Pitchford SC.

J Allergy Clin Immunol. 2015 Feb;135(2):528-38. doi: 10.1016/j.jaci.2014.09.032. Epub 2014 Oct 31.

PMID:
25445826
29.

Initial testing (stage 1) of BAL101553, a novel tubulin binding agent, by the pediatric preclinical testing program.

Kolb EA, Gorlick R, Keir ST, Maris JM, Kang MH, Reynolds CP, Lock RB, Carol H, Wu J, Kurmasheva RT, Houghton PJ, Smith MA.

Pediatr Blood Cancer. 2015 Jun;62(6):1106-9. doi: 10.1002/pbc.25329. Epub 2014 Nov 18.

30.

Initial testing (stage 1) of the PARP inhibitor BMN 673 by the pediatric preclinical testing program: PALB2 mutation predicts exceptional in vivo response to BMN 673.

Smith MA, Hampton OA, Reynolds CP, Kang MH, Maris JM, Gorlick R, Kolb EA, Lock R, Carol H, Keir ST, Wu J, Kurmasheva RT, Wheeler DA, Houghton PJ.

Pediatr Blood Cancer. 2015 Jan;62(1):91-8. doi: 10.1002/pbc.25201. Epub 2014 Sep 27.

31.

miR-33a promotes glioma-initiating cell self-renewal via PKA and NOTCH pathways.

Wang H, Sun T, Hu J, Zhang R, Rao Y, Wang S, Chen R, McLendon RE, Friedman AH, Keir ST, Bigner DD, Li QJ, Wang H, Wang XF.

J Clin Invest. 2014 Oct;124(10):4489-502. doi: 10.1172/JCI75284. Epub 2014 Sep 9.

32.

Initial solid tumor testing (stage 1) of AZD1480, an inhibitor of Janus kinases 1 and 2 by the pediatric preclinical testing program.

Houghton PJ, Kurmasheva RT, Lyalin D, Maris JM, Kolb EA, Gorlick R, Reynolds CP, Kang MH, Keir ST, Wu J, Smith MA.

Pediatr Blood Cancer. 2014 Nov;61(11):1972-9. doi: 10.1002/pbc.25175. Epub 2014 Aug 17.

33.

Profiling Hsp90 differential expression and the molecular effects of the Hsp90 inhibitor IPI-504 in high-grade glioma models.

Di K, Keir ST, Alexandru-Abrams D, Gong X, Nguyen H, Friedman HS, Bota DA.

J Neurooncol. 2014 Dec;120(3):473-81. doi: 10.1007/s11060-014-1579-y. Epub 2014 Aug 13.

34.

Mutations in IDH1, IDH2, and in the TERT promoter define clinically distinct subgroups of adult malignant gliomas.

Killela PJ, Pirozzi CJ, Healy P, Reitman ZJ, Lipp E, Rasheed BA, Yang R, Diplas BH, Wang Z, Greer PK, Zhu H, Wang CY, Carpenter AB, Friedman H, Friedman AH, Keir ST, He J, He Y, McLendon RE, Herndon JE 2nd, Yan H, Bigner DD.

Oncotarget. 2014 Mar 30;5(6):1515-25.

35.

Initial testing (stage 1) of the notch inhibitor PF-03084014, by the pediatric preclinical testing program.

Carol H, Maris JM, Kang MH, Reynolds CP, Kolb EA, Gorlick R, Keir ST, Wu J, Kurmasheva RT, Houghton PJ, Smith MA, Lock RB, Lyalin D.

Pediatr Blood Cancer. 2014 Aug;61(8):1493-6. doi: 10.1002/pbc.25026. Epub 2014 Mar 24. Erratum in: Pediatr Blood Cancer. 2014 Sep;61(9):1716. Lyalin, Dmitry [added].

36.

Initial testing (stage 1) of the investigational mTOR kinase inhibitor MLN0128 by the pediatric preclinical testing program.

Kang MH, Reynolds CP, Maris JM, Gorlick R, Kolb EA, Lock R, Carol H, Keir ST, Wu J, Lyalin D, Kurmasheva RT, Houghton PJ, Smith MA.

Pediatr Blood Cancer. 2014 Aug;61(8):1486-9. doi: 10.1002/pbc.24989. Epub 2014 Feb 20.

37.

KMT2D maintains neoplastic cell proliferation and global histone H3 lysine 4 monomethylation.

Guo C, Chen LH, Huang Y, Chang CC, Wang P, Pirozzi CJ, Qin X, Bao X, Greer PK, McLendon RE, Yan H, Keir ST, Bigner DD, He Y.

Oncotarget. 2013 Nov;4(11):2144-53.

38.

Proteasome inhibition with bortezomib induces cell death in GBM stem-like cells and temozolomide-resistant glioma cell lines, but stimulates GBM stem-like cells' VEGF production and angiogenesis.

Bota DA, Alexandru D, Keir ST, Bigner D, Vredenburgh J, Friedman HS.

J Neurosurg. 2013 Dec;119(6):1415-23. doi: 10.3171/2013.7.JNS1323. Epub 2013 Oct 4.

39.

Initial testing (stage 1) of the histone deacetylase inhibitor, quisinostat (JNJ-26481585), by the Pediatric Preclinical Testing Program.

Carol H, Gorlick R, Kolb EA, Morton CL, Manesh DM, Keir ST, Reynolds CP, Kang MH, Maris JM, Wozniak A, Hickson I, Lyalin D, Kurmasheva RT, Houghton PJ, Smith MA, Lock R.

Pediatr Blood Cancer. 2014 Feb;61(2):245-52. doi: 10.1002/pbc.24724. Epub 2013 Sep 4.

40.

Initial testing (stage 1) of the Polo-like kinase inhibitor volasertib (BI 6727), by the Pediatric Preclinical Testing Program.

Gorlick R, Kolb EA, Keir ST, Maris JM, Reynolds CP, Kang MH, Carol H, Lock R, Billups CA, Kurmasheva RT, Houghton PJ, Smith MA.

Pediatr Blood Cancer. 2014 Jan;61(1):158-64. doi: 10.1002/pbc.24616. Epub 2013 Aug 19.

41.

Affinity-matured recombinant immunotoxin targeting gangliosides 3'-isoLM1 and 3',6'-isoLD1 on malignant gliomas.

Piao H, Kuan CT, Chandramohan V, Keir ST, Pegram CN, Bao X, Månsson JE, Pastan IH, Bigner DD.

MAbs. 2013 Sep-Oct;5(5):748-62. doi: 10.4161/mabs.25860. Epub 2013 Jul 25.

42.

The integrated landscape of driver genomic alterations in glioblastoma.

Frattini V, Trifonov V, Chan JM, Castano A, Lia M, Abate F, Keir ST, Ji AX, Zoppoli P, Niola F, Danussi C, Dolgalev I, Porrati P, Pellegatta S, Heguy A, Gupta G, Pisapia DJ, Canoll P, Bruce JN, McLendon RE, Yan H, Aldape K, Finocchiaro G, Mikkelsen T, Privé GG, Bigner DD, Lasorella A, Rabadan R, Iavarone A.

Nat Genet. 2013 Oct;45(10):1141-9. doi: 10.1038/ng.2734. Epub 2013 Aug 5.

43.

Construction of an immunotoxin, D2C7-(scdsFv)-PE38KDEL, targeting EGFRwt and EGFRvIII for brain tumor therapy.

Chandramohan V, Bao X, Keir ST, Pegram CN, Szafranski SE, Piao H, Wikstrand CJ, McLendon RE, Kuan CT, Pastan IH, Bigner DD.

Clin Cancer Res. 2013 Sep 1;19(17):4717-27. doi: 10.1158/1078-0432.CCR-12-3891. Epub 2013 Jul 15.

44.

Initial testing (Stage 1) of the antibody-maytansinoid conjugate, IMGN901 (Lorvotuzumab mertansine), by the pediatric preclinical testing program.

Wood AC, Maris JM, Gorlick R, Kolb EA, Keir ST, Reynolds CP, Kang MH, Wu J, Kurmasheva RT, Whiteman K, Houghton PJ, Smith MA.

Pediatr Blood Cancer. 2013 Nov;60(11):1860-7. doi: 10.1002/pbc.24647. Epub 2013 Jun 24.

45.

Exomic sequencing of four rare central nervous system tumor types.

Bettegowda C, Agrawal N, Jiao Y, Wang Y, Wood LD, Rodriguez FJ, Hruban RH, Gallia GL, Binder ZA, Riggins CJ, Salmasi V, Riggins GJ, Reitman ZJ, Rasheed A, Keir S, Shinjo S, Marie S, McLendon R, Jallo G, Vogelstein B, Bigner D, Yan H, Kinzler KW, Papadopoulos N.

Oncotarget. 2013 Apr;4(4):572-83.

46.

Initial testing (stage 1) of eribulin, a novel tubulin binding agent, by the pediatric preclinical testing program.

Kolb EA, Gorlick R, Reynolds CP, Kang MH, Carol H, Lock R, Keir ST, Maris JM, Billups CA, Desjardins C, Kurmasheva RT, Houghton PJ, Smith MA.

Pediatr Blood Cancer. 2013 Aug;60(8):1325-32. doi: 10.1002/pbc.24517. Epub 2013 Mar 28.

47.

The effects of cannabidiol on the antigen-induced contraction of airways smooth muscle in the guinea-pig.

Dudášová A, Keir SD, Parsons ME, Molleman A, Page CP.

Pulm Pharmacol Ther. 2013 Jun;26(3):373-9. doi: 10.1016/j.pupt.2013.02.002. Epub 2013 Feb 18.

PMID:
23428645
48.

Reversing the Warburg effect as a treatment for glioblastoma.

Poteet E, Choudhury GR, Winters A, Li W, Ryou MG, Liu R, Tang L, Ghorpade A, Wen Y, Yuan F, Keir ST, Yan H, Bigner DD, Simpkins JW, Yang SH.

J Biol Chem. 2013 Mar 29;288(13):9153-64. doi: 10.1074/jbc.M112.440354. Epub 2013 Feb 13. Erratum in: J Biol Chem. 2018 Sep 28;293(39):14973.

49.

Initial testing (stage 1) of temozolomide by the pediatric preclinical testing program.

Keir ST, Maris JM, Reynolds CP, Kang MH, Kolb EA, Gorlick R, Lock R, Carol H, Morton CL, Wu J, Kurmasheva RT, Houghton PJ, Smith MA.

Pediatr Blood Cancer. 2013 May;60(5):783-90. doi: 10.1002/pbc.24368. Epub 2013 Jan 17.

50.

Initial testing (stage 1) of ganetespib, an Hsp90 inhibitor, by the Pediatric Preclinical Testing Program.

Lock RB, Carol H, Maris JM, Kang MH, Reynolds CP, Kolb EA, Gorlick R, Keir ST, Billups CA, Kurmasheva RT, Houghton PJ, Smith MA.

Pediatr Blood Cancer. 2013 Jul;60(7):E42-5. doi: 10.1002/pbc.24451. Epub 2013 Jan 9.

Supplemental Content

Support Center